{
  "disease_name": "Hyperinsulinism-hyperammonemia syndrome",
  "orpha_code": "35878",
  "drugs": [
    {
      "name": "Allogeneic adult liver-derived stem cells",
      "substance_url": "/en/drug/substance/629851?name=35878&mode=orpha&region=&status=all",
      "substance_id": "629851",
      "regulatory_url": "/en/drug/regulatory/629852?name=35878&mode=orpha&region=",
      "regulatory_id": "629852",
      "orpha_substance_code": "ORPHA:79167",
      "details": [
        "Allogeneic adult liver-derived stem cells(Medicinal product                        - 10/08/2022)Disease(s) concernedORPHA:79167 Disorder of urea cycle metabolism and ammonia detoxification",
        "Allogeneic adult liver-derived stem cells(Medicinal product                        - 10/08/2022)",
        "(Medicinal product                        - 10/08/2022)",
        "Disease(s) concernedORPHA:79167 Disorder of urea cycle metabolism and ammonia detoxification",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/629851?name=35878&mode=orpha&region=&status=all",
          "text": "Allogeneic adult liver-derived stem cells",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/79167",
          "text": "ORPHA:79167 Disorder of urea cycle metabolism and ammonia detoxification",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/629852?name=35878&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "of urea cycle metabolism and ammonia detoxification\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide",
      "substance_url": "/en/drug/substance/605146?name=35878&mode=orpha&region=&status=all",
      "substance_id": "605146",
      "regulatory_url": "/en/drug/regulatory/605147?name=35878&mode=orpha&region=",
      "regulatory_id": "605147",
      "orpha_substance_code": "ORPHA:657",
      "details": [
        "4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide(Medicinal product                        - 09/12/2020)Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
        "4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide(Medicinal product                        - 09/12/2020)",
        "(Medicinal product                        - 09/12/2020)",
        "Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/605146?name=35878&mode=orpha&region=&status=all",
          "text": "4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/657",
          "text": "ORPHA:657 Congenital isolated hyperinsulinism",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/605147?name=35878&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Exendin-(9-39)",
      "substance_url": "/en/drug/substance/371566?name=35878&mode=orpha&region=&status=all",
      "substance_id": "371566",
      "regulatory_url": "/en/drug/regulatory/572565?name=35878&mode=orpha&region=",
      "regulatory_id": "572565",
      "orpha_substance_code": "ORPHA:657",
      "details": [
        "Exendin-(9-39)(Medicinal product                        - 13/11/2019)Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
        "Exendin-(9-39)(Medicinal product                        - 13/11/2019)",
        "(Medicinal product                        - 13/11/2019)",
        "Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/371566?name=35878&mode=orpha&region=&status=all",
          "text": "Exendin-(9-39)",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/657",
          "text": "ORPHA:657 Congenital isolated hyperinsulinism",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/572565?name=35878&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Glucagon analogue linked to a human immunoglobulin Fc fragment",
      "substance_url": "/en/drug/substance/527458?name=35878&mode=orpha&region=&status=all",
      "substance_id": "527458",
      "regulatory_url": "/en/drug/regulatory/527462?name=35878&mode=orpha&region=",
      "regulatory_id": "527462",
      "orpha_substance_code": "ORPHA:657",
      "details": [
        "Glucagon analogue linked to a human immunoglobulin Fc fragment(Medicinal product                        - 25/05/2018)Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
        "Glucagon analogue linked to a human immunoglobulin Fc fragment(Medicinal product                        - 25/05/2018)",
        "(Medicinal product                        - 25/05/2018)",
        "Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/527458?name=35878&mode=orpha&region=&status=all",
          "text": "Glucagon analogue linked to a human immunoglobulin Fc fragment",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/657",
          "text": "ORPHA:657 Congenital isolated hyperinsulinism",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/527462?name=35878&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Dasiglucagon",
      "substance_url": "/en/drug/substance/489767?name=35878&mode=orpha&region=&status=all",
      "substance_id": "489767",
      "regulatory_url": "/en/drug/regulatory/489772?name=35878&mode=orpha&region=",
      "regulatory_id": "489772",
      "orpha_substance_code": "ORPHA:657",
      "details": [
        "Dasiglucagon(Medicinal product                        - 20/06/2017)Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
        "Dasiglucagon(Medicinal product                        - 20/06/2017)",
        "(Medicinal product                        - 20/06/2017)",
        "Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/489767?name=35878&mode=orpha&region=&status=all",
          "text": "Dasiglucagon",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/657",
          "text": "ORPHA:657 Congenital isolated hyperinsulinism",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/489772?name=35878&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Ersodetug",
      "substance_url": "/en/drug/substance/480436?name=35878&mode=orpha&region=&status=all",
      "substance_id": "480436",
      "regulatory_url": "/en/drug/regulatory/480438?name=35878&mode=orpha&region=",
      "regulatory_id": "480438",
      "orpha_substance_code": "ORPHA:657",
      "details": [
        "Ersodetug(Medicinal product                        - 14/07/2016)Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
        "Ersodetug(Medicinal product                        - 14/07/2016)",
        "(Medicinal product                        - 14/07/2016)",
        "Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/480436?name=35878&mode=orpha&region=&status=all",
          "text": "Ersodetug",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/657",
          "text": "ORPHA:657 Congenital isolated hyperinsulinism",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/480438?name=35878&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Glucagon",
      "substance_url": "/en/drug/substance/299535?name=35878&mode=orpha&region=&status=all",
      "substance_id": "299535",
      "regulatory_url": "/en/drug/regulatory/300868?name=35878&mode=orpha&region=",
      "regulatory_id": "300868",
      "orpha_substance_code": "ORPHA:657",
      "details": [
        "Glucagon(Medicinal product                        - 05/03/2012)Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
        "Glucagon(Medicinal product                        - 05/03/2012)",
        "(Medicinal product                        - 05/03/2012)",
        "Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/299535?name=35878&mode=orpha&region=&status=all",
          "text": "Glucagon",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/657",
          "text": "ORPHA:657 Congenital isolated hyperinsulinism",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/300868?name=35878&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Single strand 20-mer antisense oligonucleotide (ASO) targeting a CPS1 regulatory RNA with a triantennary N-acetylgalactosamine (GalNAc) ligand attached at the 3' end",
      "substance_url": "/en/drug/substance/688360?name=35878&mode=orpha&region=&status=all",
      "substance_id": "688360",
      "regulatory_url": "/en/drug/regulatory/688517?name=35878&mode=orpha&region=",
      "regulatory_id": "688517",
      "orpha_substance_code": "ORPHA:79167",
      "details": [
        "Single strand 20-mer antisense oligonucleotide (ASO) targeting a CPS1 regulatory RNA with a triantennary N-acetylgalactosamine (GalNAc) ligand attached at the 3' end(Medicinal product                        - 11/09/2024)Disease(s) concernedORPHA:79167 Disorder of urea cycle metabolism and ammonia detoxification",
        "Single strand 20-mer antisense oligonucleotide (ASO) targeting a CPS1 regulatory RNA with a triantennary N-acetylgalactosamine (GalNAc) ligand attached at the 3' end(Medicinal product                        - 11/09/2024)",
        "(Medicinal product                        - 11/09/2024)",
        "Disease(s) concernedORPHA:79167 Disorder of urea cycle metabolism and ammonia detoxification",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/688360?name=35878&mode=orpha&region=&status=all",
          "text": "Single strand 20-mer antisense oligonucleotide (ASO) targeting a CPS1 regulatory RNA with a triantennary N-acetylgalactosamine (GalNAc) ligand attached at the 3' end",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/79167",
          "text": "ORPHA:79167 Disorder of urea cycle metabolism and ammonia detoxification",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/688517?name=35878&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "of urea cycle metabolism and ammonia detoxification\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Solution stable glucagon analog",
      "substance_url": "/en/drug/substance/684497?name=35878&mode=orpha&region=&status=all",
      "substance_id": "684497",
      "regulatory_url": "/en/drug/regulatory/684707?name=35878&mode=orpha&region=",
      "regulatory_id": "684707",
      "orpha_substance_code": "ORPHA:657",
      "details": [
        "Solution stable glucagon analog(Medicinal product                        - 17/06/2024)Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
        "Solution stable glucagon analog(Medicinal product                        - 17/06/2024)",
        "(Medicinal product                        - 17/06/2024)",
        "Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/684497?name=35878&mode=orpha&region=&status=all",
          "text": "Solution stable glucagon analog",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/657",
          "text": "ORPHA:657 Congenital isolated hyperinsulinism",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/684707?name=35878&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Glucagon infusion",
      "substance_url": "/en/drug/substance/413075?name=35878&mode=orpha&region=&status=all",
      "substance_id": "413075",
      "regulatory_url": "/en/drug/regulatory/413076?name=35878&mode=orpha&region=",
      "regulatory_id": "413076",
      "orpha_substance_code": "ORPHA:657",
      "details": [
        "Glucagon infusion(Medicinal product                        - 25/09/2014)Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
        "Glucagon infusion(Medicinal product                        - 25/09/2014)",
        "(Medicinal product                        - 25/09/2014)",
        "Disease(s) concernedORPHA:657 Congenital isolated hyperinsulinism",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/413075?name=35878&mode=orpha&region=&status=all",
          "text": "Glucagon infusion",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/657",
          "text": "ORPHA:657 Congenital isolated hyperinsulinism",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/413076?name=35878&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Glycerol phenylbutyrate",
      "substance_url": "/en/drug/substance/222387?name=35878&mode=orpha&region=&status=all",
      "substance_id": "222387",
      "regulatory_url": "/en/drug/regulatory/238146?name=35878&mode=orpha&region=",
      "regulatory_id": "238146",
      "orpha_substance_code": "ORPHA:79167",
      "details": [
        "Glycerol phenylbutyrate(Medicinal product                        - 27/04/2009)Disease(s) concernedORPHA:79167 Disorder of urea cycle metabolism and ammonia detoxification",
        "Glycerol phenylbutyrate(Medicinal product                        - 27/04/2009)",
        "(Medicinal product                        - 27/04/2009)",
        "Disease(s) concernedORPHA:79167 Disorder of urea cycle metabolism and ammonia detoxification",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/222387?name=35878&mode=orpha&region=&status=all",
          "text": "Glycerol phenylbutyrate",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/79167",
          "text": "ORPHA:79167 Disorder of urea cycle metabolism and ammonia detoxification",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/238146?name=35878&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "of urea cycle metabolism and ammonia detoxification\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    }
  ],
  "processing_timestamp": "2025-07-07T06:00:33.146983",
  "run_number": 1,
  "total_drugs_found": 11,
  "search_url": "https://www.orpha.net/en/drug?diseaseName=Hyperinsulinism-hyperammonemia+syndrome&orphaCode=35878&name=35878&region=&mode=orpha&status=all",
  "search_params": {
    "diseaseName": "Hyperinsulinism-hyperammonemia syndrome",
    "orphaCode": "35878",
    "name": "35878",
    "region": "",
    "mode": "orpha",
    "status": "all"
  }
}